What are the updates in the 2026 Malaysian dengue clinical practice guideline compared with the previous version?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 27, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Unable to Provide Comparison: 2026 Malaysian Dengue Guideline Not Available

I cannot identify specific changes in the 2026 Malaysian dengue clinical practice guideline compared to previous versions because the provided evidence does not contain the actual 2026 Malaysian dengue CPG or any previous Malaysian dengue guidelines for comparison.

What the Evidence Actually Contains

The available evidence includes:

  • US CDC guidelines 1 from 2019 focused on dengue and Zika virus diagnostic testing - these are American, not Malaysian guidelines
  • Research studies about Malaysian dengue guidelines 2, 3, 4, 5 that discuss the quality, awareness, utilization, and adherence to existing Malaysian dengue CPGs, but do not provide the actual guideline content or specify what changed between versions
  • Public health studies 6, 7, 8 from 2026 examining dengue prevention knowledge, surveillance methods, and mosquito control practices in Malaysia - these are research papers, not clinical practice guidelines

Key Findings from Available Research

A 2026 systematic review 2 assessed the methodological quality of dengue CPGs globally from 2009-2025 across 18 countries, finding only 6 high-quality guidelines among 29 reviewed. However, this study does not detail specific Malaysian guideline updates or compare versions.

Studies from 2017-2019 3, 4, 5 documented that Malaysian doctors showed high awareness (99% in public facilities, 84% in private) of existing dengue CPGs, but adherence varied widely (7.1-100% across different clinical components), with better compliance in hospital versus outpatient settings.

What Would Be Needed

To answer your question accurately, I would need:

  • The actual 2026 Malaysian Ministry of Health dengue CPG document
  • The previous version of the Malaysian dengue CPG for direct comparison
  • Official documentation of what specific recommendations changed between editions

Without access to the actual guideline documents, I cannot provide the specific changes you are requesting.

References

2
Research

The methodological quality of dengue clinical practice guidelines globally. A systematic review.

QJM : monthly journal of the Association of Physicians, 2026

Related Questions

According to Malaysian dengue guidelines, when does the critical phase begin, how long does it last, and what monitoring and fluid management are required?
Can diphenhydramine be used in a patient with dengue who has severe pruritus?
What are the causes, complications, and recommended treatment for dengue infection?
What CBC findings are typical in dengue, and how frequently should the CBC be repeated to monitor the critical phase?
Can a dengue-positive mother safely breastfeed her 5-month-old infant?
What is the recommended treatment for prominent left internal iliac vein distribution on the pelvic floor and uterine subzero veins indicating pelvic venous congestion?
In a patient with an A1C of 8% who is taking basal insulin, tirzepatide (15 mg weekly) and metformin (2000 mg daily), will decreasing the basal insulin dose cause the A1C to increase?
What oral alternative medication can be used after a seizure is stopped with IV benzodiazepine?
What non‑benzodiazepine sleep medication would you recommend for a female oncology patient experiencing depressive symptoms, insomnia, and increased appetite?
What is Azstarys (serdexmethylphenidate and methylphenidate)?
What data exist on the use of N‑acetylcysteine (NAC) in adult COVID‑19 patients, and what are the recommended dosing and safety considerations?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.